[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"cardiac-sarcoidosis\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:cardiac-sarcoidosis":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,16,0,[8,45,69,99,123,159,180,207,240,268,295,320,349,374,394,415],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":29,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":33,"lastUpdatePostDateStruct":34,"startDateStruct":37,"completionDateStruct":39,"leadSponsor":41,"locationsCount":44},"100331323","phase-3-cardiac-sarcoidosis-randomized-trial-100331323",false,"NCT03593759","Cardiac Sarcoidosis Randomized Trial","Cardiac Sarcoidosis Multi-Center Randomized Controlled Trial","CHASM-CS-RCT","Inclusion Criteria:\n\n(i) Cardiac sarcoidosis presenting with one or more of the following clinical findings:\n\n* advanced conduction system disease (defined as Mobitz II AV block or third degree AV block)\n* significant sinus node dysfunction (defined as average HR less than 40bpm when awake and\u002For sustained atrial arrhythmias)\n* non- sustained or sustained ventricular arrhythmia\n* left ventricular dysfunction (LVEF \\\u003C 50%)\n* right ventricular dysfunction (RVEF \\\u003C 40%)\n\nAND\n\n(ii) No alternative explanation for clinical features\n\nAND\n\n(iii) Nuclear Imaging within six-months of enrollment consisting of FDG-PET scan with FDG uptake suggestive of active CS and myocardial perfusion imaging\n\nAND ONE OR BOTH OF FOLLOWING\n\n(iv) Positive biopsy for Sarcoid (either EMB or extra-cardiac)\n\n(v) CT Chest showing features consistent with pulmonary sarcoidosis and\u002For mediastinal and\u002For hilar lymphadenopathy\n\nExclusion Criteria:\n\n1. Current or recent (within two months) non-topical treatment for sarcoidosis\n2. Current Oral\u002FIV treatment of duration greater than 5 days\n3. Currently taking Methotrexate or Prednisone for another health condition\n4. Intolerance or contra-indication to Methotrexate or Prednisone\n5. Patient does not meet all of the above listed inclusion criteria\n6. Patient is unable or unwilling to provide informed consent\n7. Patient is included in another randomized clinical trial\n8. Patient has a contraindication to PET imaging or is unlikely to tolerate due to severe claustrophobia\n9. Pregnancy (all women of child bearing age and potential will have a negative BHCG test before enrollment)\n10. Breastfeeding\n11. Women of childbearing age who refuse to use a highly effective and medically acceptable form of contraception throughout the study\n12. Patients for whom the investigator believes that the trial is not in the interest of the patient","ALL","18 Years",{"count":20,"type":21},194,"ESTIMATED","INTERVENTIONAL",[24],"PHASE3","Prospective randomized controlled trial comparing low dose Prednisone(or Prednisolone)\u002FMethotrexate combination to standard dose Prednisone(or Prednisolone) in patients diagnosed with acute active clinically manifest cardiac sarcoidosis and not yet treated.\n\nThe Investigators hypothesize that low dose Prednisone(or Prednisolone)\u002FMethotrexate combination will be as effective as standard dose Prednisone(or Prednisolone), and result in significantly better quality of life and less toxicity than standard dose Prednisone(or Prednisolone).",[27,28],"Cardiac Sarcoidosis","Sarcoidosis",[27,30,31],"Prednisone (or Prednisolone)","Methotrexate","RECRUITING","2026-06-29",{"date":35,"type":36},"2026-07-02","ACTUAL",{"date":38,"type":36},"2019-01-15",{"date":40,"type":21},"2026-12",{"name":42,"class":43},"Ottawa Heart Institute Research Corporation","OTHER",31,{"id":46,"slug":47,"hasResults":11,"nctId":48,"briefTitle":49,"officialTitle":50,"acronym":51,"eligibilityCriteria":52,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":53,"enrollmentInfo":54,"targetDuration":4,"studyType":56,"phases":4,"briefSummary":57,"conditions":58,"keywords":59,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":60,"lastUpdatePostDateStruct":61,"startDateStruct":63,"completionDateStruct":65,"leadSponsor":67,"locationsCount":68},"100169296","cardiac-sarcoidosis-multi-center-prospective-cohort-100169296","NCT01477359","Cardiac Sarcoidosis Multi-Center Prospective Cohort","Cardiac Sarcoidosis Multi-Center Prospective Cohort Study","CHASM-CS","Inclusion Criteria:\n\nTo diagnose Clinically Manifest CS all following criteria must be met:\n\n(i) Positive biopsy\\* for Sarcoid (either EMB or extra-cardiac) AND\u002FOR (ii) CT Chest highly suggestive of pulmonary sarcoidosis AND (iii) one or more of the following clinical features:\n\n* advanced conduction system disease (sustained Mobitz II AV block or third degree AV block)\n* non- sustained or sustained ventricular arrhythmia\n* ventricular dysfunction (LVEF \\\u003C 50% and\u002For RVEF \\\u003C 40%) AND (iv) No alternative explanation for clinical features AND (v) FDG-PET suggestive of active CS\n\nTo diagnose clinically silent CS all of the following criteria must be met\n\n(i) Biopsy proven extra-cardiac sarcoidosis\n\nAND\u002FOR (ii) CT Chest highly suggestive of pulmonary sarcoidosis\n\nAND (iii) CMR suggestive of cardiac sarcoidosis\n\nAND (iv) Does not have criteria for clinically manifest CS ie. should not have any of following\n\n* advanced conduction system disease (sustained Mobitz II AV block or third degree AV block)\n* non- sustained or sustained ventricular arrhythmia\n* ventricular dysfunction (LVEF \\\u003C 50% and\u002For RVEF \\\u003C 40%)\n\nPatients with negative CMR will be designated as 'extra-cardiac sarcoidosis with no evidence of CS' and followed as control\n\nExclusion Criteria:\n\n* unable or unwilling to provide informed consent\n* patients who are pregnant or lactating\n* patients with known claustrophobia\n* age \\\u003C 18 years","99 Years",{"count":55,"type":21},1500,"OBSERVATIONAL","Recent data has shown that sarcoidosis, presenting initially with cardiac manifestations (CS) of either conduction system disease or cardiomyopathy and sustained VT, is not uncommon. A Canadian physician survey found that most physicians do not investigate for CS as a possibility in these situations. Thus many patients with clinically important CS are going un-diagnosed. A study from Finland showed that missing the diagnosis of CS in these patients' leads to significant mortality and morbidity.\n\nThere are no published clinical consensus guidelines on treatment of CS. Corticosteroid therapy is advocated by most experts. This is based on very modest data from small retrospective observational studies using variable definitions of clinical response. The effect of corticosteroid treatment on the clinical course of CS has not been studied in prospective studies and will be one of the aims of this project. Recent physician surveys regarding CS, in Canada and the US, found that current clinical practice varies widely. The 2008 American College of Cardiology\u002FAmerican Heart Association\u002FHeart Rhythm society guidelines recommend implantation of a defibrillator (Class IIa recommendation) to prevent sudden cardiac death. The most recent Canadian device therapy guidelines do not mention CS.\n\nA multi-center collaborative approach to study CS is greatly needed.\" The investigators propose exactly that i.e. a multi-center prospective cohort to start to answer clinical questions. The investigators have formed the CANADIAN CARDIAC SARCOIDOSIS RESEARCH GROUP. The group includes respirologists with an interest in sarcoidosis, cardiac electrophysiologists, cardiac imaging specialists with extensive experience in imaging of sarcoidosis and biostatisticians. The research will be in two phases; a registry of current diagnostic approaches, treatment and prognosis, and a randomized clinical trial of the effect of corticosteroid treatment on the clinical course of cardiac sarcoidosis.",[27],[28],"2026-06-23",{"date":62,"type":36},"2026-06-24",{"date":64,"type":36},"2012-08",{"date":66,"type":21},"2035-12",{"name":42,"class":43},14,{"id":70,"slug":71,"hasResults":11,"nctId":72,"briefTitle":73,"officialTitle":73,"acronym":74,"eligibilityCriteria":75,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":76,"targetDuration":4,"studyType":56,"phases":4,"briefSummary":78,"conditions":79,"keywords":83,"overallStatus":88,"whyStopped":4,"lastUpdateSubmitDate":89,"lastUpdatePostDateStruct":90,"startDateStruct":92,"completionDateStruct":94,"leadSponsor":96,"locationsCount":98},"100637828","exosome-based-omic-signatures-of-disease-activity-in-cardiac-sarcoidosis-exodacs-100637828","NCT07604220","Exosome-based Omic Signatures of Disease Activity in Cardiac Sarcoidosis (EXODACS)","EXODACS","Inclusion Criteria\n\n* Adults ≥18 years.\n* Patients referred to the Cardiac Sarcoid Clinic with a clinical suspicion or a previously confirmed diagnosis of cardiac sarcoidosis.\n* Undergoing FDG-PET as part of standard care.\n* Ability to provide informed consent.\n\nExclusion Criteria\n\n• Inability to provide informed consent.",{"count":77,"type":21},115,"The purpose of this study is to develop a prospective cohort of patients with and without cardiac sarcoidosis as well as active and inactive disease to develop a prospective biobank from which exosome analysis of peripheral blood will derive unique biomarkers of disease activity in cardiac sarcoidosis.",[27,80,81,82],"Sarcoidosis of the Heart","Sarcoidosis With Myocarditis","Sarcoidosis, Cardiac",[84,85,86,87],"cardiac sarcoidosis","FDG-PET","disease activity","proteomics","NOT_YET_RECRUITING","2026-05-18",{"date":91,"type":36},"2026-05-22",{"date":93,"type":21},"2026-07",{"date":95,"type":21},"2028-07",{"name":97,"class":43},"Mayo Clinic",1,{"id":100,"slug":101,"hasResults":11,"nctId":102,"briefTitle":103,"officialTitle":104,"acronym":4,"eligibilityCriteria":105,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":106,"targetDuration":4,"studyType":22,"phases":108,"briefSummary":110,"conditions":111,"keywords":4,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":114,"lastUpdatePostDateStruct":115,"startDateStruct":117,"completionDateStruct":119,"leadSponsor":121,"locationsCount":98},"100477643","phase-2-68gaga-pentixafor-petct-in-acute-myocardial-inflammation-100477643","NCT05499637","[68Ga]Ga-PentixaFor PET\u002FCT in Acute Myocardial Inflammation","Pilot Study to Evaluate the Accuracy of [68Ga]Ga-PentixaFor PET\u002FCT in the Diagnosis of Three Clinical Entities of Acute Myocardial Inflammation","Inclusion Criteria:\n\n* signed written informed consent\n* male or female\n* age ≥ 18 years\n* patients with suspicion CS (group II) or ICIM (group III) or in their regular follow-up in their first year after HT (group I)\n* SOC clinical follow-up at the cardiology department in CHUV.\n\nExclusion Criteria:\n\nThe presence of any one of the following exclusion criteria will lead to exclusion of the participant:\n\n* absence of a signed written informed consent\n* patients aged \\\u003C 18 years\n* claustrophobia\n* myocardial ischemia in non-invasive perfusion test or coronarography in group II and III\n* clinically unstable cardiovascular conditions, including:\n\n  * clinically unstable brady-tachyarrhythmia\n  * severe and symptomatic hypo- or hypertension with documented systolic blood pressure \\\u003C 90 mmHg or ≥220 mmHg respectively\n  * cardiogenic shock.\n* women who are pregnant or breast feeding\n* intention to become pregnant during the course of the study in group II\n* previous enrolment into the current study\n* moderate to severe renal insufficiency (GFR \\\u003C 45 mL\u002Fmin\u002F1,73 m2), with contra-indication to the administration of Gadolinium in group II and III\n* enrollment of the investigator, his\u002Fher family members, employees and other dependent persons\n* history of any disease or relevant physical or psychiatric condition or abnormal physical finding which may interfere with the study objectives at the investigator judgment\n* insufficient knowledge of project language, inability to give consent or to follow procedures\n* the patient makes use of his\u002Fher \"right not to know\" and refuses to be informed about incidental findings",{"count":107,"type":21},69,[109],"PHASE2","Acute myocardial inflammation is an heterogenic syndrome involving different clinical pathologies with different outcome. For the purpose of this study protocol, we focuse on three entities of this syndrome, namely the acute cellular cardiac allograft rejection (ACR), cardiac sarcoidosis (CS) and the immune checkpoint inhibitor induced myocarditis (ICIM), for which non-invasive diagnosis remains challenging.\n\nSince accurate diagnosis of myocardial inflammation in an early stage is crucial, this study aims to investigate the accuracy of \\[68Ga\\]Ga-PentixaFor as a marker of for the presence of inflammatory cells (T-lymphocytes and M1) in described patients.\n\nThe identification of a correlation between \\[68Ga\\]Ga-PentixaFor myocardial accumulation with currently accepted diagnostic tools would open up new ways to non-invasively diagnose acute myocardial inflammation.",[112,27,113],"Acute Cellular Graft Rejection","Myocarditis Due to Drug","2026-05-05",{"date":116,"type":36},"2026-05-11",{"date":118,"type":36},"2023-01-17",{"date":120,"type":21},"2027-01",{"name":122,"class":43},"John O. Prior",{"id":124,"slug":125,"hasResults":11,"nctId":126,"briefTitle":127,"officialTitle":128,"acronym":4,"eligibilityCriteria":129,"healthyVolunteers":130,"sex":17,"minAge":4,"maxAge":4,"enrollmentInfo":131,"targetDuration":4,"studyType":56,"phases":4,"briefSummary":133,"conditions":134,"keywords":4,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":150,"lastUpdatePostDateStruct":151,"startDateStruct":153,"completionDateStruct":155,"leadSponsor":157,"locationsCount":158},"100289553","mayo-avc-registry-and-biobank-100289553","NCT03049254","Mayo AVC Registry and Biobank","Identification of Novel Genetic Variants and Biomarkers of Disease Progression in Arrhythmogenic Cardiomyopathy","Inclusion Criteria:\n\n* Patients with a diagnosis of a non-MI SCA who survived\n* Patients with a non-MI SCD\n* Patient with a SCA associated with seizures, epilepsy, syncope, drowning and near-drowning, where a cardiomyopathy is suspected\n* Family member of a patient diagnosed with primary cardiomyopathy (including HCM, idiopathic DCM, AVC)\n\nExclusion Criteria:\n\n* Patients with a clear, unambiguous known cause of SCA or SCD such as myocardial infarction or heart failure secondary to ischemic heart disease\n* Significant coronary artery disease (Epicardial coronary artery stenosis \\>50%) which can explain degree of LV dysfunction\n* Those unwilling to provide written consent or assent",true,{"count":132,"type":21},1000,"Arrhythmogenic ventricular cardiomyopathy (AVC) is a genetic condition which affects the heart and can lead to heart failure and rhythm problems, of which, sudden cardiac arrest or death is the most tragic and dangerous. Diagnosis and screening of blood-relatives is very difficult as the disease process can be subtle, but sufficient enough, so that the first event is sudden death.\n\nThe Mayo Clinic AVC Registry is a collaboration between Mayo Clinic, Rochester, USA and Papworth Hospital, Cambridge University Hospitals, Cambridge, UK. The investigators aim to enroll patients with a history of AVC or sudden cardiac death which may be due to AVC, from the US and UK. Family members who are blood-relatives will also be invited, including those who do not have the condition. Data collected include symptoms, ECG, echocardiographic, MRI, Holter, loop recorder, biopsies, exercise stress testing, blood, buccal and saliva samples.\n\nObjectives of the study:\n\n1. Discover new genes or altered genes (variants) which cause AVC\n2. Identify biomarkers which predict (2a) disease onset, (2b) disease progression, (2c) and the likelihood of arrhythmia (ventricular, supra-ventricular and atrial fibrillation)\n3. Correlate genotype with phenotype in confirmed cases of AVC followed longitudinally using clinical, electrocardiographic and imaging data.\n4. Characterize desmosomal changes in buccal mucosal cells with genotype and validate with gold-standard endomyocardial biopsies",[135,136,137,138,139,140,141,142,143,144,28,145,27,146,147,148,149],"Arrhythmogenic Right Ventricular Cardiomyopathy","Cardiomyopathies","Heart Diseases","Cardiovascular Diseases","Sudden Cardiac Arrest","Sudden Cardiac Death","Arrhythmogenic Right Ventricular Dysplasia","Arrhythmogenic Ventricular Cardiomyopathy","Familial Dilated Cardiomyopathy","Cardiovascular Abnormalities","Cardiac Arrhythmia","Myocarditis","Inflammatory Cardiomyopathy","Ventricular Tachycardia","Right Ventricular Outflow Tract Ventricular Tachycardia","2026-04-22",{"date":152,"type":36},"2026-04-27",{"date":154,"type":36},"2018-02-09",{"date":156,"type":21},"2027-03",{"name":97,"class":43},2,{"id":160,"slug":161,"hasResults":11,"nctId":162,"briefTitle":163,"officialTitle":164,"acronym":4,"eligibilityCriteria":165,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":166,"targetDuration":4,"studyType":22,"phases":168,"briefSummary":169,"conditions":170,"keywords":4,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":171,"lastUpdatePostDateStruct":172,"startDateStruct":174,"completionDateStruct":176,"leadSponsor":178,"locationsCount":98},"100605173","phase-2-repurposing-tilmanocept-for-cardiac-sarcoidosis-100605173","NCT07159074","Repurposing Tilmanocept for Cardiac Sarcoidosis","Repurposing Tc 99m Tilmanocept Imaging for Cardiac Sarcoidosis","Inclusion Criteria:\n\nCohort 1:\n\n1. The participant has provided written informed consent with HIPAA (Health Information Portability and Accountability Act) or equivalent authorization before the initiation of any study-related procedures.\n2. Women of reproductive potential must have a negative urine pregnancy test at the time of the study.\n3. The participant is at least 18 years of age.\n4. The participant has a histological diagnosis sarcoidosis and meets 2014 HRS, 2014 WASOG, or 2016 JCS criteria for cardiac sarcoidosis.\n5. The participant has had a clinically indicated cardiac PET-CT showing cardiac activity in the past 14 days.\n6. The participant has had a prior cardiac MRI with delayed enhancement in pattern consistent with cardiac sarcoidosis as defined in the AHA Scientific Statement on the Diagnosis and Management of Cardiac Sarcoidosis (2024).\n\nCohort 2:\n\n1. The participant has provided written informed consent with HIPAA (Health Information Portability and Accountability Act) or equivalent authorization before the initiation of any study-related procedures.\n2. Women of reproductive potential must have a negative urine pregnancy test at the time of the study.\n3. The participant is at least 18 years of age.\n4. Cardiac sarcoidosis has been clinically excluded.\n5. The participant has an arrhythmogenic, non-ischemic cardiomyopathy defined as the presence of a cardiomyopathy with a history of recurrent (more than 1 episode) ventricular tachycardia, atrial arrhythmias, high grade AV block not due to ischemic heart disease\n\nExclusion Criteria:\n\n1. The participant is pregnant or lactating.\n2. The participant size or weight is not compatible with imaging per the investigator.\n3. The participant has renal insufficiency as demonstrated by a glomerular filtration rate of \\\u003C 30 mL\u002Fmin.\n4. The participant has hepatic insufficiency as demonstrated by ALT (alanine aminotransferase \\[SGPT\\]) or AST (aspartate aminotransferase \\[SGOT\\]) greater than 3 times the upper limit of normal.\n5. The participant has any severe, acute, or chronic medical conditions and\u002For psychiatric conditions and\u002For laboratory abnormalities that would impart, in the judgment of the investigator, excess risk associated with study participation or study drug administration that would deem the subject inappropriate for study participation.\n6. The participant has a known allergy to or has had an adverse reaction to dextran exposure.\n7. The participant has received an investigational product within 30 days prior to the Tc 99m tilmanocept administration (Day 0).\n8. The participant has received any radiopharmaceutical within 7 days or 10 half-lives prior to the administration of Tc 99m tilmanocept (Day 0).",{"count":167,"type":21},15,[109],"The purpose of this study is to see if Tc 99m Tilmanocept SPECT\u002FCT imaging can be used to identify cardiac sarcoidosis.",[27],"2026-03-24",{"date":173,"type":36},"2026-03-27",{"date":175,"type":36},"2025-09-17",{"date":177,"type":21},"2026-12-31",{"name":179,"class":43},"Duke University",{"id":181,"slug":182,"hasResults":11,"nctId":183,"briefTitle":184,"officialTitle":185,"acronym":4,"eligibilityCriteria":186,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":187,"enrollmentInfo":188,"targetDuration":4,"studyType":22,"phases":190,"briefSummary":191,"conditions":192,"keywords":193,"overallStatus":88,"whyStopped":4,"lastUpdateSubmitDate":198,"lastUpdatePostDateStruct":199,"startDateStruct":201,"completionDateStruct":203,"leadSponsor":205,"locationsCount":98},"100582828","phase-2-a-trial-of-baricitinib-in-patients-with-cardiac-sarcoidosis-100582828","NCT06868381","A Trial of Baricitinib in Patients With Cardiac Sarcoidosis","A Phase IIa, Single-Site, Open-Label Trial of Baricitinib in Patients With Cardiac Sarcoidosis","Key Inclusion Criteria:\n\n* Diagnosis of cardiac sarcoidosis based on one of the following pathways:\n\n  * Histological Diagnosis\n\n    * Myocardial or extracardiac biopsy demonstrating non-caseating granuloma with no alternative cause identified AND\n    * Abnormal FDG uptake on cardiac PET-CT conducted within six weeks of Screening, in a pattern consistent with active cardiac sarcoidosis AND\n    * Exclusion of other causes for cardiac manifestations\n  * Clinical Diagnosis\n\n    * One or more of the following is present:\n\n      * Steroid +\u002F- immunosuppressant responsive cardiomyopathy or heart block\n      * Unexplained reduced LVEF (\\\u003C 40%) and\u002For segmental wall motion abnormalities not related to coronary artery disease or another defined cause\n      * Unexplained sustained (spontaneous or induced) VT\n      * Mobitz type II 2nd degree heart block or 3rd degree heart block\n      * CT chest and\u002For FDG PET-CT showing features consistent with pulmonary sarcoidosis and\u002For hilar lymphadenopathy AND\n    * Abnormal FDG uptake on cardiac PET-CT conducted within 6 weeks of Screening, in a pattern consistent with active cardiac sarcoidosis AND\n    * Exclusion of other causes for cardiac manifestations\n* Active cardiac sarcoidosis based on abnormal FDG uptake on cardiac PET-CT conducted within six weeks of Screening, in a pattern consistent with active cardiac sarcoidosis\n* No current treatment with immunosuppressive medications other than a steroid-sparing medication (including methotrexate, leflunomide, azathioprine, or mycophenolate mofetil), and\u002For prednisone (or equivalent) at a dose of ≤ 20mg daily at Baseline\n\nKey Exclusion Criteria:\n\n* Receipt of a non-biologic DMARD or immunosuppressive agent other than methotrexate, leflunomide, azathioprine, mycophenolate mofetil, hydroxychloroquine, or glucocorticoids within 28 days prior to screening\n* Receipt of a bDMARD or tsDMARD, including non-depleting B-cell-directed therapy (eg, belimumab), T cell costimulatory blockade (eg, abatacept), TNF-alpha inhibition (eg, infliximab, adalimumab, etanercept, golimumab, certolizumab pegol), interleukin-6 inhibition (eg, tocilizumab, sarilumab), interleukin-1 inhibition (eg, anakinra), JAK inhibition (eg, tofacitinib, upadacitinib, baricitinib), or other biologic immunomodulatory agent within 28 days prior to screening\n* Receipt of any biologic B cell-depleting therapy (eg, rituximab, ocrelizumab, obinutuzumab, ofatumumab, inebilizumab) in the 6 months prior to screening; receipt of such a B cell-depleting agent in the period 6-12 months prior to screening is exclusionary unless B cell counts have returned to ≥ LLN\n* History of venous thromboembolism (VTE) or an increased risk for VTE\n* Current smoking\n* Estimated glomerular filtration rate \\\u003C 30 mL\u002Fmin\u002F1.73 m2 by Modification of Diet in Renal Disease Study (MDRD) equation\n* Blood tests at screening that meet any of the following criteria:\n\n  * Hemoglobin \\\u003C 7.5 g\u002FdL\n  * Neutrophils \\\u003C 1000\u002Fmm3\n  * Absolute lymphocyte count \\\u003C 500\u002Fmm3\n  * Platelets \\\u003C 100 x 109\u002FL\n* Subjects with the following abnormal liver function tests:\n\n  * Aspartate aminotransferase (AST) \\> 2x ULN\n  * Alanine aminotransferase (ALT) \\> 2x ULN\n  * Total bilirubin (TBL) \\> 2x ULN unless AST, ALT, and hemoglobin are within central laboratory normal range and the patient has a known history of Gilbert syndrome\n* Active, clinically significant infection at the time of Screening\n* Active malignancy or history of malignancy that was active within the last 5 years, except as follows:\n\n  * In situ carcinoma of the cervix following apparently curative therapy \\> 12 months prior to screening,\n  * Cutaneous basal cell or squamous cell carcinoma following apparently curative therapy, or\n  * Prostate cancer treated with radical prostatectomy or radiation therapy with curative intent \\> 3 years prior to screening and without known recurrence or current treatment","85 Years",{"count":189,"type":21},10,[109],"The goal of this clinical trial is to learn if baricitinib in combination with a background steroid-sparing medication can treat active cardiac sarcoidosis in adults. The main question it aims to answer is:\n\n\\- In patients with active cardiac sarcoidosis, does treatment with baricitinib improve cardiac sarcoidosis disease activity as assessed by changes on cardiac FDG-PET\u002FCT?\n\nParticipants will:\n\n* Take baricitinib in combination with a steroid-sparing therapy for up to 16 weeks\n* Visit the clinic every two to four weeks for checkups and tests\n* Be asked to complete questionnaires to see how they feel on baricitinib and medication diaries to record when they take baricitinib",[27],[194,195,84,196,197],"baricitinib","sarcoidosis","Janus kinase inhibitor","JAK inhibitor","2026-02-06",{"date":200,"type":36},"2026-02-10",{"date":202,"type":21},"2026-04-01",{"date":204,"type":21},"2028-12-01",{"name":206,"class":43},"Stanford University",{"id":208,"slug":209,"hasResults":11,"nctId":210,"briefTitle":211,"officialTitle":212,"acronym":4,"eligibilityCriteria":213,"healthyVolunteers":130,"sex":17,"minAge":4,"maxAge":4,"enrollmentInfo":214,"targetDuration":215,"studyType":56,"phases":4,"briefSummary":216,"conditions":217,"keywords":224,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":231,"lastUpdatePostDateStruct":232,"startDateStruct":234,"completionDateStruct":236,"leadSponsor":238,"locationsCount":98},"100618805","precision-diagnosis-and-risk-stratification-of-rare-cardiomyopathies-based-on-novel-cardiac-magnetic-resonance-techniques-100618805","NCT07336394","Precision Diagnosis and Risk Stratification of Rare Cardiomyopathies Based on Novel Cardiac Magnetic Resonance Techniques","Multimodality Imaging (Cardiovascular Magnetic Resonance Imaging, Echocardiography, and Nuclear Medicine Imaging) in the Screening, Diagnosis and Risk Stratification of Rare Cardiomyopathies - a Multicenter Study","Inclusion Criteria:\n\n* Patients who have received a cardiac magnetic resonance examination since 2010 and have a suspicion of rare cardiomyopathy.\n\nExclusion Criteria:\n\n* Severe arrhythmia;\n* Severe primary cardiac valvular disease;\n* Refuse to participate in the study.",{"count":132,"type":21},"10 Years","What is this study about? This research is focused on improving the care for people with rare heart muscle diseases, known as rare cardiomyopathies. These are uncommon conditions where the heart muscle becomes stiff, thick, or enlarged, making it harder for the heart to pump blood. Because they are rare, they can be difficult to diagnose and manage.\n\nThe investigators are testing new, advanced ways of using a heart scan called a Cardiac Magnetic Resonance (CMR). Participants can think of a CMR as a very powerful camera that takes detailed pictures of their heart without using radiation.\n\nWhat is the study trying to learn? Better Diagnosis: The investigators want to see if these new scanning techniques can help us identify these rare heart conditions more clearly and accurately. This means patients could get a correct diagnosis sooner.\n\nPersonalized Risk Assessment: The investigators want to see if the scan can help us understand the future risk for each patient better. For example, can it help predict which patients are more likely to have a heart rhythm problem or need specific treatments? This helps doctors create a care plan that is tailored just for participants.\n\nWhat does this mean for participants? If participants choose to take part, they will undergo a CMR scan that uses these new techniques. By participating, they will be helping us find better ways to diagnose and care for people with their condition in the future. The goal is to turn uncertainty into clearer, more personalized information for patients and families.",[218,219,220,221,27,222,223],"Danon Disease","Fabry Disease","Cardiac Amyloidosis","Noonan Syndrome","Glycogen Storage Disease","Idiopathic Cardiomyopathy",[225,226,227,228,229,230],"cardiovascular magnetic resonance imaging","early diagnosis","prognosis","rare cardiomyopathies","nuclear medicine imaging","echocardiography","2026-01-19",{"date":233,"type":36},"2026-01-21",{"date":235,"type":36},"2010-01-01",{"date":237,"type":21},"2030-12-30",{"name":239,"class":43},"Chinese Academy of Medical Sciences, Fuwai Hospital",{"id":241,"slug":242,"hasResults":11,"nctId":243,"briefTitle":244,"officialTitle":245,"acronym":4,"eligibilityCriteria":246,"healthyVolunteers":130,"sex":17,"minAge":4,"maxAge":4,"enrollmentInfo":247,"targetDuration":4,"studyType":56,"phases":4,"briefSummary":249,"conditions":250,"keywords":251,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":259,"lastUpdatePostDateStruct":260,"startDateStruct":262,"completionDateStruct":264,"leadSponsor":266,"locationsCount":98},"100555346","diagnostic-utility-of-sglt12-inhibition-to-facilitate-myocardial-glucose-suppression-100555346","NCT06510894","Diagnostic Utility of SGLT1\u002F2 Inhibition to Facilitate Myocardial Glucose Suppression","Diagnostic Utility of SGLT1\u002F2 Inhibition to Facilitate Myocardial Glucose Suppression During Evaluation of Cardiac Inflammation on FDG-PET","Inclusion Criteria:\n\n1. Adult patients, at least 18 years of age\n2. No history of cardiovascular disease, including hypertension, hyperlipidemia, diabetes mellitus, heart failure, coronary artery disease, cardiac surgery, arrhythmias per medical record review and\u002For self-report\n3. No history of chronic liver or kidney disease per medical record review and\u002For self-report.\n4. Participants must be informed of the investigational nature of this study and provide written informed consent in accordance with institutional and federal guidelines prior to study-specific procedures.\n\nExclusion Criteria:\n\n1. Females who are pregnant or breast-feeding will not be eligible for this study. Female participants of child-bearing potential will have a urine pregnancy test during the screening visit and prior to FDG injection.\n2. Participants who are currently taking diuretics for any indication.\n3. Participants with an eGFR level \\\u003C30 mL\u002Fmin\u002F1.73m2.\n4. Inability to tolerate imaging procedures in the opinion of the investigator or treating physician.\n5. Any other medical or psychological condition that, in the opinion of the investigator would compromise the subject's safety or successful participation in the study.",{"count":248,"type":21},40,"This is a pilot mechanistic study of the diagnostic utility of sodium-glucose cotransporter-1\u002F2 inhibition (SGLT1\u002F2) on myocardial glucose suppression on FDG PET\u002FCT. The investigators will test whether the addition of a SGLT1\u002F2 inhibitor (SGLT1\u002F2i) plus the standard dietary modification (ketogenic diet) will provide enhanced myocardial glucose suppression. The primary objective is to assess rates of complete myocardial glucose suppression (MGS) with 7 days of sotagliflozin 400 mg QD among healthy volunteers on a background of 1 day (N=20) or 3 days (N=20) of the KD. The secondary goal is to investigate the relationship between sotagliflozin, targeted metabolite levels, and myocardial glucose utilization on FDG-PET.\n\nParticipants will be asked to:\n\n* undergo a screening visit that includes blood tests, vitals, and questions regarding health history\u002Fmedications\n* take the provided sotagliflozin as instructed for 7 days leading up to the scan\n* follow a ketogenic diet as instructed for 1 or 3 days leading up to the scan\n* undergo an FDG PET\u002FCT scan, which includes vitals and blood draws",[27],[195,252,253,254,255,256,257,258],"Cardiac Sacroidosis","SGLT1\u002F2 Inhibition","Myocardial Glucose Suppression","Ketogenic Diet","sotagliflozin","Healthy volunteer","PET\u002FCT","2026-01-06",{"date":261,"type":36},"2026-01-07",{"date":263,"type":36},"2024-11-20",{"date":265,"type":21},"2027-12-31",{"name":267,"class":43},"University of Pennsylvania",{"id":269,"slug":270,"hasResults":11,"nctId":271,"briefTitle":272,"officialTitle":272,"acronym":273,"eligibilityCriteria":274,"healthyVolunteers":130,"sex":17,"minAge":275,"maxAge":276,"enrollmentInfo":277,"targetDuration":4,"studyType":56,"phases":4,"briefSummary":279,"conditions":280,"keywords":4,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":286,"lastUpdatePostDateStruct":287,"startDateStruct":289,"completionDateStruct":291,"leadSponsor":293,"locationsCount":98},"100547562","cardiomyopathies-and-heart-muscle-diseases-cardiac-imaging-in-the-evaluation-of-myocardial-fibrosis-transition-100547562","NCT06409585","Cardiomyopathies and Heart Muscle Diseases: Cardiac Imaging in the Evaluation of Myocardial Fibrosis Transition","CHIEFTain","Inclusion Criteria:\n\nHFpEF cohort\n\n* Male or female between 30 to 90 years old\n* Provision of informed consent prior to any study specific procedures\n* Patients with symptomatic heart failure with preserved ejection fraction as defined by the presence of heart failure symptoms (dyspnoea, reduced exercise tolerance, fatigue), signs (elevated jugular venous pressure, pulmonary crackles, peripheral oedema) as well as echocardiographic features (preserved left ventricular systolic function (\\>50%) and reduced diastolic function with septal e' \\\u003C7cm\u002Fs or lateral e' \\\u003C10cm\u002Fs).\n\nHypertrophic cardiomyopathy cohort\n\n* Male or female between 30 to 90 years old\n* Provision of informed consent prior to any study specific procedures\n* Established diagnosis of hypertrophic cardiomyopathy: left ventricular wall thickness \\>15mm by any imaging modality without a loading condition to explain the hypertrophy OR\n* Left ventricular wall thickness of \\>13 mm by any imaging modality in the presence of a genetic or non-genetic component, supported by other features including family history, non-cardiac symptoms, ECG changes and laboratory tests.\n\nHypertensive heart disease cohort\n\n* Male or female between 30 to 90 years old\n* Provision of informed consent prior to any study specific procedures\n* Diagnosis of essential hypertension for at least 1 year with evidence of left ventricular hypertrophy on echocardiography (left ventricular mass index \\>98 g\u002Fm2 and relative wall thickness \\>0.42)\n\nArrhythmogenic cardiomyopathy\n\n* Male or female between 30 to 90 years old\n* Provision of informed consent prior to any study specific procedures\n* Diagnosis of arrhythmogenic right ventricular cardiomyopathy based on the International Task Force 2010 criteria\n\nMyocarditis cohort\n\n* Male or female between 30 to 90 years old\n* Provision of informed consent prior to any study specific procedures\n* Diagnosis of myocarditis in the past month defined with the following features\n\n  * Chest pain\n  * Evidence of pericarditis (pericardial rub, ST- segment elevation or pericardial effusion)\n  * Elevated serum troponin\n  * Unobstructed coronary arteries on coronary angiogram OR\n  * Cardiac magnetic resonance imaging evidence of myocarditis (subepicardial or mid-wall late gadolinium enhancement\n\nTakotsubo cardiomyopathy cohort\n\n* Male or female between 30 to 90 years old\n* Provision of informed consent prior to any study specific procedures\n* Diagnosis of takotsubo cardiomyopathy in the past month as defined by European Society of Cardiology guidelines 2018\n\nCardiac sarcoidosis cohort\n\n* Male or female between 30 to 90 years old\n* Provision of informed consent prior to any study specific procedures\n* Diagnosis of cardiac sarcoidosis for at least 1 year based on expert consensus opinion with\n\n  * Histological diagnosis from a myocardial biopsy OR\n  * Histological diagnosis of extra-cardiac sarcoid AND\n\nOne or more of following is present\n\n* Steroid +\u002F- immunosuppressant responsive cardiomyopathy or heart block\n* Unexplained reduced LVEF (\\\u003C40%)\n* Unexplained sustained (spontaneous or induced) VT\n* Mobitz type II 2nd degree heart block or 3rd degree heart block\n* Patchy uptake on dedicated cardiac PET (in a pattern consistent with CS)\n* Late Gadolinium Enhancement on CMR (in a pattern consistent with CS)\n* Positive gallium uptake (in a pattern consistent with CS) AND\n* Other causes for the cardiac manifestation(s) have been reasonably excluded\n\nExclusion Criteria:\n\n* Inability or unwilling to give informed consent.\n* History of claustrophobia or inability to tolerate supine position for the PET\u002FMR or PET\u002FCT scans.\n* Impaired renal function with eGFR of \\\u003C30 mL\u002Fmin\u002F1.73 m2.\n* Women who are pregnant or breastfeeding.\n* Iodine or gadolinium contrast allergy\n* Contra-indication to CT scanning","30 Years","90 Years",{"count":278,"type":21},290,"Heart scarring, also known as fibrosis, plays a major role in a lot of heart muscle abnormalities. These abnormalities of the heart muscle can lead to major issues such as symptoms of heart failure, dangerous heart rhythm disturbances and even death. However, a lot of these conditions are still not fully understood and treatment options are limited. We here aim to use a new radioactive dye called 68Ga-FAPI to identify patterns and the activity of heart muscle scarring. This radioactive dye is being used in humans particularly in identifying and monitoring cancers and has shown promise in identifying scarring in the heart as well. This will help us not only understand the underlying disease process and risk stratify these patients but also potentially help us develop new targeted therapies that can affect heart muscle scarring. Participants will undergo a baseline MRI scan using this new dye and a plain MRI scan will repeated 12-18 months after to see if there are any changes in the process.",[281,282,27,283,284,285,146],"Heart Failure With Preserved Ejection Fraction","Hypertrophic Cardiomyopathy","Hypertensive Heart Disease","Tako Tsubo Cardiomyopathy","Arrhythmogenic Right Ventricular Cardiomyopathy 1","2025-08-18",{"date":288,"type":36},"2025-08-19",{"date":290,"type":36},"2023-05-01",{"date":292,"type":21},"2028-01-01",{"name":294,"class":43},"University of Edinburgh",{"id":296,"slug":297,"hasResults":11,"nctId":298,"briefTitle":299,"officialTitle":300,"acronym":4,"eligibilityCriteria":301,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":302,"enrollmentInfo":303,"targetDuration":4,"studyType":22,"phases":305,"briefSummary":306,"conditions":307,"keywords":308,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":313,"lastUpdatePostDateStruct":314,"startDateStruct":316,"completionDateStruct":318,"leadSponsor":319,"locationsCount":158},"100566865","phase-2-rilonacept-in-subjects-with-cardiac-sarcoidosis-100566865","NCT06660732","Rilonacept in Subjects With Cardiac Sarcoidosis","A RandomizEd PhAse II TrIal of Rilonacept in Subjects With Cardiac Sarcoidosis (REPAIR-CS)","Inclusion Criteria:\n\n1. Able to comprehend and willing to sign an ICF and to abide by the study restrictions and requirements\n2. Age ≥ 18 years and ≤ 80 years\n3. Female subjects must be:\n\n   * postmenopausal, defined as at least 12 months post cessation of menses (without an alternative medical cause), or\n   * permanently sterile following documented hysterectomy, bilateral salpingectomy, bilateral oophorectomy, or tubal ligation, or having a male partner with vasectomy as affirmed by the subject, or\n   * nonpregnant, nonlactating, and having agreed to use an effective method of contraception (i.e., hormonal contraception, intrauterine device \\[IUD\\], or double barrier methods such as condom plus diaphragm or diaphragm plus spermicide or condom plus spermicide) from Screening Visit 1 until 5 months after study drug administration, if sexually active.\n4. Male subjects must have documented vasectomy or must use double barrier methods of contraception (such as condom plus diaphragm or diaphragm plus spermicide or condom plus spermicide) or use condoms plus hormonal contraceptives or condoms plus IUD with their female partners of childbearing potential from randomization to 3 months after the last dose of study drug administration. Male subjects must agree to refrain from donating sperm during this time period.\n5. Routine adult vaccinations should be up to date and\u002For offered at least 2 weeks prior to randomization according to regional and national guidelines based on medical history or presence of risk factors, in the opinion of the Investigator.\n\n   Cardiac Inclusion Criteria:\n6. Has a diagnosis of cardiac sarcoidosis by the Heart Rhythm Society (HRS) expert consensus statement on the diagnosis and management of arrhythmias associated with cardiac sarcoidosis, or the Japanese Circulation Society 2016 Guideline on diagnosis and treatment of cardiac sarcoidosis (Terasaki 2019)\n7. Three or more segments of active FDG uptake on PET scan within 8 weeks of randomization, despite standard therapy\n8. Willing to wear an ambulatory cardiac rhythm monitor at the specified timepoints\n\nExclusion Criteria\n\n1. Unable or unwilling to provide informed consent\n2. Weight \\>380 pounds (172 kilograms)\n3. Women who are pregnant or lactating or women of childbearing age who refuse to use a highly effective and medically acceptable form of contraception throughout the study\n4. Planned to initiate TNF-α antagonist therapy over the course of the study.\n5. Known claustrophobia, or difficulty completing prior PET scan procedure(s)\n6. Left ventricular end-systolic diameter (LVESD) \\> 60 mm on echocardiogram\n7. Other systemic immune disorder(s) or other disorder(s) that require treatment with immunomodulators or immunosuppressants\n8. Has received, or is scheduled to receive after randomization, mechanical circulatory support\n9. Congenital, valvular, and\u002For coronary artery disease that could explain the severity of cardiac dysfunction\n10. Known hypersensitivity to rilonacept (KPL-914) or to any of its excipients\n11. Meets the following TB criteria:\n\n    1. History of active TB prior to screening OR\n    2. History of latent TB that was not adequately treated prior to screening OR\n    3. Signs or symptoms suggestive of active TB (e.g., new cough of \\>14 days in duration or a change in chronic cough, persistent fever, unintentional weight loss, or night sweats) upon review of medical history and\u002For physical examination at screening OR\n    4. Recent close contact with a person with active TB OR\n    5. Positive or indeterminate Interferon Gamma Release Assay (IGRA) test results or results from another positive TB test at screening based on acceptable local clinical practice\n12. Use of the following immunosuppressive or immunomodulatory therapies (see also Section 5.6 \"Prior and Concomitant Therapy\") within the timeframe prior to randomization as defined below for each drug class or category:\n\n    1. INCREASE in dose of existing immunosuppression\u002Fimmunomodulation drug or INITIATION of new immunosuppression\u002Fimmunomodulation drug in the one month prior to or ON or AFTER the date of the eligibility\u002Fbaseline FDG-PET scan until the date of randomization.\n    2. Anakinra within 1 week prior to first dose of study drug; canakinumab within 8 weeks prior to the first dose of study drug; abatacept within 8 weeks prior to first dose of study drug;\n    3. TNF inhibitors within 2-8 weeks of or 5 half-lives (etanercept within 2 weeks; infliximab, certolizumab, golimumab, or adalimumab within 8 weeks) prior to first dose of study drug, whichever is longer.\n    4. Rituximab within 6 months prior to the first dose of study drug unless levels of CD20+ B cells have been assessed and have returned to normal.\n    5. Cyclosporine A (CsA) within 4 weeks prior to the first dose of study drug.\n13. Received any investigational product within 30 days or 5 half-lives (if the half-life is known) of an investigational product (whichever is longer) prior to first dose of study drug\n14. Concurrent enrollment in another clinical study, with the exception of observational studies\n15. Uncontrolled hypertension (systolic blood pressure \\>170 mmHg and diastolic blood pressure \\>110 mmHg\n16. Uncontrolled thyroid disease (serum TSH \\\u003C 0.1 mU\u002FL or \\> 10 mU\u002FL)\n17. Uncontrolled diabetes mellitus (serum glucose \\> 180 mg\u002FdL fasting or HbA1c \\>9%)\n18. Estimated glomerular filtration rate (eGFR) \\\u003C30mL\u002Fmin\n19. Major surgery within 8 weeks prior to screening or planned major surgery within 6 months after first dose of study drug.\n20. Transplanted organs (except corneal transplant performed more than 3 months prior to first dose of study drug).\n21. Severe active, recurrent, or chronic infection (per PI discretion), or any episode of infection requiring hospitalization or treatment with a course of IV antibiotics within 12 weeks before screening. Subjects with a history of severe opportunistic infection (per PI discretion) are also excluded from the study.\n22. High risk of infection (e.g., history of hereditary or acquired immune deficiency disorder), a history of an infected joint prosthesis at any time with that prosthesis still in situ, leg ulcers, indwelling urinary catheter, or persistent or recurrent chest infections.\n23. Chronic active HBV infection, defined as:\n\n    1. HBV surface antigen positive\n    2. HBV anti-core antibody positive but anti-surface antibody negative\n24. Presence of symptoms indicative of COVID-19 infection (per PI discretion), unless a PCR test for COVID-19 has been reported as negative within the previous 7 days or is acquired prior to randomization.\n25. History of cancer within the last 5 years from screening, except for basal and squamous cell carcinoma of the skin or in situ carcinoma of the cervix treated and considered cured.\n26. Has screening laboratory test results meeting any of the following criteria:\n\n    1. Hemoglobin level \\\u003C 8.0 g\u002FdL\n    2. WBC count \\\u003C 3.0 × 103\u002FµL\n    3. Neutrophil count \\\u003C1.5 × 103\u002FµL\n    4. Platelet count \\\u003C 100 × 103\u002FµL\n    5. Total bilirubin level \\>1.5 × ULN unless the test results are consistent with those for Gilbert's syndrome\n    6. AST or ALT values \\> 2 × ULN\n27. Any condition that, in the opinion of the investigator, could interfere with evaluation of the investigational product or interpretation of subject safety or confound the results of the study","80 Years",{"count":304,"type":21},60,[109],"The primary objective of this study is to evaluate the effect of rilonacept, added to standard therapy and compared with standard therapy alone, on improvement in myocardial inflammation in subjects with cardiac sarcoidosis after 24 weeks of therapy.",[27],[27,309,146,310,311,312],"Sarcoid Myocarditis","Inflammation","PET scan","Heart Failure","2025-08-12",{"date":315,"type":36},"2025-08-15",{"date":317,"type":36},"2025-03-05",{"date":156,"type":21},{"name":97,"class":43},{"id":321,"slug":322,"hasResults":11,"nctId":323,"briefTitle":324,"officialTitle":324,"acronym":325,"eligibilityCriteria":326,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":327,"targetDuration":4,"studyType":22,"phases":329,"briefSummary":331,"conditions":332,"keywords":334,"overallStatus":88,"whyStopped":4,"lastUpdateSubmitDate":340,"lastUpdatePostDateStruct":341,"startDateStruct":343,"completionDateStruct":345,"leadSponsor":347,"locationsCount":158},"100595195","evaluation-of-the-impact-of-a-patient-education-protocol-on-the-quality-of-18f-fdg-pet-imaging-indicated-for-investigation-of-cardiac-inflammation-100595195","NCT07029295","Evaluation of the Impact of a Patient Education Protocol on the Quality of 18F-FDG PET Imaging Indicated for Investigation of Cardiac Inflammation","CARTEP","Inclusion Criteria:\n\n* Presence of a prescription validated by the nuclear medicine department for an 18F-FDG PET scan for the detection of inflammation of cardiac inflammation or infection\n* Age greater than or equal to 18\n* Membership of a social security scheme or equivalent\n* Patients with an e-mail address\n* Patients who understand French\n* Collection of patient consent\n\nExclusion Criteria:\n\n* Pregnancy or breast-feeding\n* Patients (inpatients or outpatients) already on a diet (including ketogenic)\n* Patients who do not understand protocol\n* Patients deprived of liberty by judicial or administrative decision\n* Patients under legal protection (guardianship\u002Ftrusteeship)\n* Patients under court protection",{"count":328,"type":21},138,[330],"NA","The aim of this study is to assess the impact of implementing a patient education and preparation protocol for FDG PET (18F-FDG PET) imaging on the quality of imaging results.\n\n18F-FDG (18Fluor-FluoroDesoxyGlucose) PET (Positron Emission Tomography) is indicated for the diagnosis of cardiac inflammation. To detect cardiac inflammation, the myocardium (heart muscle) must be prevented from absorbing glucose from the diet (FDG). To achieve this, patient preparation is essential. Poor preparation can compromise the interpretation of results, causing diagnostic delay.\n\nTo answer the research question, the investigators plan to include 138 people with suspected infective endocarditis or cardiac sarcoidosis, in two institutions of the Assistance Publique - Hôpitaux de Paris: Hôpital Européen Georges Pompidou and Hôpital Cochin-Port-Royal, located respectively at 20 rue Leblanc 75015 Paris and 27 rue du Faubourg Saint-Jacques 75014 Paris.",[333,27],"Infective Endocarditis",[335,336,337,84,338,339],"18F-FDG","PET","infective endocarditis","patient preparation","patient education protocol","2025-06-11",{"date":342,"type":36},"2025-06-19",{"date":344,"type":21},"2025-07-01",{"date":346,"type":21},"2027-08-31",{"name":348,"class":43},"Assistance Publique - Hôpitaux de Paris",{"id":350,"slug":351,"hasResults":11,"nctId":352,"briefTitle":353,"officialTitle":354,"acronym":355,"eligibilityCriteria":356,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":357,"targetDuration":4,"studyType":22,"phases":359,"briefSummary":360,"conditions":361,"keywords":362,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":366,"lastUpdatePostDateStruct":367,"startDateStruct":369,"completionDateStruct":371,"leadSponsor":373,"locationsCount":98},"100512596","evaluation-of-the-prognostic-value-of-petmri-in-cardiac-sarcoidosis-100512596","NCT05954507","Evaluation of the Prognostic Value of PET\u002FMRI in Cardiac Sarcoidosis","Prospective Comparative Multicenter Study Evaluating the Prognostic Interest of PET\u002FMRI in Cardiac Sarcoidosis","SARCASTIM","Inclusion Criteria:\n\n* Age ≥ 18 years\n* Sarcoidosis defined according to ATS\u002FERS\u002FWASOG criteria\n* Suspicion of cardiac involvement in sarcoidosis:\n\n  * Clinical manifestations (syncope, lipothymia, persistent palpitations, signs of heart failure) and\u002For\n  * Cardiac rhythm or conduction disorder (Mobitz type 2 atrioventricular block (AVB), AVB 3, right or left bundle branch block, Q wave in at least 2 leads, ventricular arrhythmia (ventricular mono\u002Fpolymorphic complexes\\> 1000 per 24 h, ventricular tachycardia, ventricular fibrillation), unexplained sustained VT or epsilon wave) and\u002For\n  * Compatible cardiac ultrasound abnormality: left ventricular dilatation, septal thickening or wall thinning (especially basal), segmental kinetic disorder and wall aneurysm without coronary anomaly, altered left ventricular ejection fraction, altered diastolic function, altered right ventricular systolic function.\n* Informed patient consent\n* Membership of a social security scheme\n\nExclusion Criteria:\n\n* Psychiatric illness not controlled by treatment\n* Claustrophobia\n* Known pregnancy or breast-feeding patient\n* Unbalanced diabetes (influence on carbohydrate metabolism for PET)\n* Previous infarction or known coronary disease\n* Known allergy to gadolinium and fluoro-desoxyglucose and their excipients\n* Renal insufficiency (Clairance \\\u003C 30 mL\u002Fmin\u002F1.73m2)\n* Implanted pacemaker not compatible with a 3 Teslas magnetic field\n* Patients with ocular metallic foreign bodies, pacemakers, neurostimulators, cochlear implants, metallic heart valves, vascular clips formerly implanted on cranial aneurysms and, in general, any non-removably implanted electronic medical equipment\n* Inability or refusal to follow a low-carbohydrate diet for 24 hours, followed by a 6-hour fast required prior to the examination\n* Patient unable to hold a 10-second apnea.\n* Patient deprived of liberty by judicial or administrative decision\n* Patient under legal protection (guardianship, curatorship)\n* Participation in other interventional research involving the human person or being in the exclusion period following previous research involving the human person\n* Patients under AME\n\nExclusion criteria (post signature of consent) for women of reproductive age :\n\n\\- Positive pregnancy test result after inclusion",{"count":358,"type":21},180,[330],"Cardiac damage is the second leading cause of death in patients with sarcoidosis, after lung damage. Today's challenge is to diagnose the disease as effectively as possible, and to develop tools for better risk stratification, especially for sudden death, in order to better target therapies and implantable devices, such as corticoids and immunosuppressant.\n\nThe hypothesis is that combined PET (Positron Emission Tomography)\u002FMRI (Magnetic Resonance Imaging) could be a relevant prognostic marker of progression, and would significantly improve diagnostic performance in patients with suspected cardiac sarcoidosis (CS). This study will also make it possible to distinguish sequellar fibrosis lesions from granulomatous lesions and assess the therapeutic response. Incorporating PET\u002FMRI into the diagnostic strategy for patients with suspected CS could therefore improve their management.",[27],[363,364,336,365],"Cardiac sarcoidosis","Combined PET\u002FMRI","MRI","2025-03-27",{"date":368,"type":36},"2025-04-02",{"date":370,"type":36},"2025-03-07",{"date":372,"type":21},"2030-03-07",{"name":348,"class":43},{"id":375,"slug":376,"hasResults":11,"nctId":377,"briefTitle":378,"officialTitle":379,"acronym":380,"eligibilityCriteria":381,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":382,"targetDuration":4,"studyType":56,"phases":4,"briefSummary":384,"conditions":385,"keywords":4,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":386,"lastUpdatePostDateStruct":387,"startDateStruct":389,"completionDateStruct":391,"leadSponsor":392,"locationsCount":98},"100526159","macrophage-petct-imaging-using-64cu-dotatate-for-the-diagnosis-of-cardiac-sarcoidosis-100526159","NCT06131112","Macrophage PET\u002FCT Imaging Using 64Cu-DOTATATE for the Diagnosis of Cardiac Sarcoidosis","Macrophage PET\u002FCT Imaging for the Diagnosis of Cardiac Sarcoidosis","CuDOSIS","Inclusion Criteria:\n\n* Age =\\> 18 years\n* Group A: 22 patients with clinically suspected cardiac sarcoidosis Group B: 22 patients with known cardiac sarcoidosis Group C: Up to 10 patients with clinically suspected or confirmed acute lymphocytic myocarditis Group D: 22 patients with NET without known inflammatory heart disease who have previously been scanned with 64Cu-DOTATATE PET\u002FCT as part of their routine diagnostic work-up or follow-up (control group)\n\nExclusion Criteria:\n\n* Severe obesity (weight \\> 140 kg)\n* Pregnancy (negative point-of-care urine\u002Fserum human chorion gonadotropin is required in all fertile women)\n* Severe claustrophobia\n* Known allergy to 64Cu-DOTATATE\n* Clinically critical condition which makes PET\u002FCT impossible\n* Diabetes with insulin dependence",{"count":383,"type":21},76,"The purpose of the CuDOSIS study is to examine the diagnostic value of activated macrophage imaging in patients with or under evaluation for cardiac sarcoidosis. The PET\u002FCT tracer 64Cu-DOTATATE is used as a tool to identify activated macrophages. The trial is an open-label prospective study. The study will include 54 participants from the Department of Cardiology and the Department of Clinical Physiology, Nuclear Medicine, and PET at Rigshospitalet. Further, the study will include data from 22 patients with NET who have been scanned with 64Cu-DOTATATE PET\u002FCT previously as negative controls.\n\nParticipants will be included in the following groups:\n\nGroup A: 22 patients with clinically suspected cardiac sarcoidosis Group B: 22 patients with known cardiac sarcoidosis Group C: Up to 10 patients with clinically suspected or confirmed acute lymphocytic myocarditis Group D: 22 patients with NET without known inflammatory heart disease who have previously been scanned with 64Cu-DOTATATE PET\u002FCT as part of their routine diagnostic work-up or follow-up (control group)",[27],"2023-11-14",{"date":388,"type":36},"2023-11-18",{"date":390,"type":36},"2023-11-01",{"date":120,"type":21},{"name":393,"class":43},"Rigshospitalet, Denmark",{"id":395,"slug":396,"hasResults":11,"nctId":397,"briefTitle":398,"officialTitle":399,"acronym":400,"eligibilityCriteria":401,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":402,"targetDuration":404,"studyType":56,"phases":4,"briefSummary":405,"conditions":406,"keywords":4,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":407,"lastUpdatePostDateStruct":408,"startDateStruct":410,"completionDateStruct":411,"leadSponsor":413,"locationsCount":98},"100419099","diagnostic-criteria-in-cardiac-sarcoidosis-100419099","NCT04737317","Diagnostic Criteria in Cardiac Sarcoidosis","Evaluation of Diagnostic Criteria in Cardiac Sarcoidosis - an Observational Study","ELDORADO","Inclusion Criteria:\n\n* patients with suspected CS due to the following presentations:\n\n  1. age \\\u003C 65 years and new higher degree AV block, causative coronary artery disease excluded\n  2. age \\\u003C 65 years and new ventricular tachycardia, causative coronary artery disease excluded\n  3. age \\\u003C 65 years and ventricular tachycardia, causative coronary artery disease excluded\n  4. extracardiac sarcoidosis and cardiac involvement suggested (palpitations, abnormal ECG, abnormal echocardiography)\n\nTo diagnose CS one of the following diagnostic tools will be used:\n\nA) World Association of Sarcoidosis and Other Granulomatous Disorders (WASOG)\n\nB) Heart Rhythm Society expert consensus statement on the diagnosis and management of arrhythmias associated with cardiac sarcoidosis\n\nC) Japanese Society of Nuclear Cardiology (JSNC)\n\nPatients whit histological confirmation from myocardial tissue fullfil will be defined as proven CS. (Group 1)\n\nPatients with clinical and imaging findings highly suggesting CS, but without histological confirmation from myocardial biopsy will be defined as probable CS (Group 2)\n\nPatients who do not fullfil the criteria or exhibiting findings suggesting an alternative, more likely diagnosis, will be considered as unlikely CS (Group 3)\n\nExclusion Criteria:\n\n* unable or unwilling to provide informed consent\n* patients who are pregnant or lactating\n* noncompliant patients refusing the recommended therapy\n* age \\\u003C 18 years",{"count":403,"type":21},100,"2 Years","The purpose of the study is to evaluate the accuracy of the current diagnostic criteria of cardiac sarcoidosis.",[27],"2023-05-08",{"date":409,"type":36},"2023-05-09",{"date":290,"type":36},{"date":412,"type":21},"2027-01-01",{"name":414,"class":43},"Heart Center Leipzig - University Hospital",{"id":416,"slug":417,"hasResults":11,"nctId":418,"briefTitle":419,"officialTitle":420,"acronym":4,"eligibilityCriteria":421,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":422,"targetDuration":423,"studyType":56,"phases":4,"briefSummary":424,"conditions":425,"keywords":4,"overallStatus":88,"whyStopped":4,"lastUpdateSubmitDate":426,"lastUpdatePostDateStruct":427,"startDateStruct":429,"completionDateStruct":431,"leadSponsor":433,"locationsCount":4},"100500218","biomaterial-collection---and-analysis-in-cardiac-sarcoidosis-100500218","NCT05793398","Biomaterial Collection - and Analysis in Cardiac Sarcoidosis","Pathomechanisms in Patients With Cardiac Sarcoidosis and Other Inflammatory and Familial Cardiomyopathies of Similar Phenotypic Appearance","Inclusion Criteria:\n\n(a) patients with a history of symptomatic cardiac sarcoidosis\u002Finflammatory cardiomyopathy or b) patients with newly diagnosed heart failure with cardiac arrhythmias (ventricular tachycardia, conduction disturbances, etc.) that may indicate sarcoidosis or inflammatory cardiomyopathy or c) patients with image morphological suspicion of cardiac sarcoidosis or inflammatory cardiomyopathy (MRI, PET-CT) or (d) patients who require or have received a ventricular assist device (VAD) or cardiac transplantation due to suspected cardiac sarcoidosis or inflammatory cardiomyopathy and (e) written informed consent has been obtained from patients for study participation and consent for analysis of patient samples. Studies on pseudoanonymized samples will only be performed with appropriately signed informed consent.\n\nExclusion Criteria:\n\n1. Patients with psychiatric illness that impairs business or insight capacity.\n2. Patients with chronic heart failure due to coronary artery disease or valvular vitiation.\n3. severe underlying disease other than sarcoidosis that is likely to result in death within one year.",{"count":403,"type":21},"5 Years","Cardiac sarcoidosis (CS) is a complex disease that is characterized by the formation of inflammatory granulomas in the myocardium. The exact underlying pathophysiology of the disease is not yet fully understood, but it is believed to be related to dysregulation of the immune system. Despite significant progress in recent years, the disease remains difficult to diagnose, and there is a high risk of severe complications such as life-threatening cardiac arrhythmias, severe heart failure, and sudden cardiac death in affected patients.\n\nMoreover, the clinical presentation of CS can be similar to other inflammatory heart diseases or familial cardiomyopathies. Thus, it is challenging to differentiate between these diseases, which can lead to a delayed diagnosis and poor prognosis. It is unclear whether certain genetic variants play a role in the clinical course and prognosis of CS, which highlights the need for more research in this area.\n\nThe diagnosis of CS requires cardiac or extracardiac biopsy with granuloma detection, which is an invasive and complex procedure. Consequently, the disease is thought to be underdiagnosed, and many affected patients may not receive timely treatment, resulting in excess mortality. Early diagnosis and immunosuppressive treatment, as well as defibrillator implantation if necessary, are crucial in delaying disease progression, preventing complications, and improving prognosis.\n\nTo better understand the key molecular pathological mechanisms underlying the development and maintenance of CS, a prospective, multicenter, exploratory study has been initiated. The project involves the collection, storage, and analysis of biological samples from blood, myocardium, and lymph nodes of patients with cardiac sarcoidosis or cardiomyopathies that present clinically and image morphologically similar. The samples will be used for scientific investigations on disease mechanisms of cardiomyopathies as well as for identification of new biomarkers in cardiomyopathy diagnostics and for follow-up of therapeutic measures.\n\nThe study will employ a range of classical biochemical methods such as ELISA, RIA, as well as more modern methods of molecular biology (single cell sequencing, single nucleus sequencing) and systems biology (genomics, metabolomics, or proteomics) to identify key molecular pathological mechanisms in the development and maintenance of CS.\n\nIn addition, genetic analysis will be performed to investigate cardiomyopathy- and ion channel-associated genetic variants, which is critical for improving diagnostics and early, individualized therapy. The study will be conducted on a multicenter basis, with the Heart Center Leipzig serving as the initiator and lead center and the University Hospital Leipzig as the second study center. Biochemical and molecular biological analyses will be performed on behalf of the study management at the Heart Center Leipzig, the University Hospital Leipzig, and the Erich and Hanna Klessmann Institute for Cardiovascular Research and Development of the Heart and Diabetes Center NRW and Max Delbrück Center for Molecular Medicine in Berlin.\n\nIn conclusion, CS is a complex and challenging disease that requires further research to better understand its underlying mechanisms and improve diagnostic and therapeutic strategies. The prospective, multicenter, exploratory study will provide valuable insights into the disease's key molecular pathological mechanisms and identify new biomarkers for better diagnostics and individualized therapy.",[27],"2023-03-30",{"date":428,"type":36},"2023-03-31",{"date":430,"type":21},"2023-04-01",{"date":432,"type":21},"2029-04-01",{"name":414,"class":43}]